TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
TXMD'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
TherapeuticsMD Inc'in en son EPS'si $ olup, $ beklentilerini .
TherapeuticsMD Inc TXMD'ün son çeyrekteki geliri nasıl performans gösterdi?
TherapeuticsMD Inc'in son çeyrek geliri $
TherapeuticsMD Inc'in gelir tahmini nedir?
Wall Street analistine göre, TherapeuticsMD Inc'in gelir tahmini $ ile $ arasında değişmektedir.
TherapeuticsMD Inc'in kazanç kalite puanı nedir?
TherapeuticsMD Inc'in kazanç kalite puanı B+/54.56014'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
TherapeuticsMD Inc kazançlarını ne zaman rapor eder?
TherapeuticsMD Inc'in bir sonraki kazanç raporu 2026-02-10'te bekleniyor